Clinical trials: Stage III Skin Cancer
Melanoma
Safety and Efficacy of Intramuscular Electrotransfer of Plasmid AMEP in Patients Suffering From Advanced or Metastatic Melanoma
The objective of the present trial is: to determine the dose limiting toxicity (DLT), maximal tolerated dose (MTD) and recommended phase 2 dose (RP2D) of intramuscular electrotransferred Plasmid AMEP in patients with advanced or…
- Trial name
- AIMM (NCT01764009)
- Testing
- naked DNA coding for protein AMEP
- Where
- 4 sites in France, Slovenia
- Sponsor
- Valerio Therapeutics
Breast Cancer
Letrozole as Early Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer
This is a prospective open-label one-arm phase III trial designed to evaluate the safety and efficacy of letrozole 2.5 mg administered orally daily for 24 months as adjuvant therapy in postmenopausal patients with primary breast…
- Trial name
- NCT00332852
- Testing
- Letrozole
- Where
- 53 sites in Germany
- Volunteers
- 655 people
- Sponsor
- Novartis Pharmaceuticals
Melanoma
A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)
The purpose of this study is to determine the rate and frequency of high-grade (CTCAE v4.0 Grade 3 or higher), treatment-related, select adverse events in subjects with histologically confirmed stage III (unresectable) or stage…
- Trial name
- NCT02156804
- Testing
- Nivolumab (BMS-936558)
- Where
- 170 sites in Austria, Belgium and 18 more
- Volunteers
- 1,009 people
- Sponsor
- Bristol-Myers Squibb
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Cutaneous Melanoma
PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma
This is an international multicenter, open-label, randomized controlled trial (RCT) of single-agent intralesional PV-10 versus systemic chemotherapy or intralesional oncolytic viral therapy to assess treatment of locally advanced…
- Trial name
- NCT02288897
- Testing
- PV-10 (10% rose bengal disodium), Dacarbazine, temozolomide or talimogene laherparepvec
- Where
- 23 sites in United States, France and 3 more
- Volunteers
- 20 people
- Sponsor
- Provectus Biopharmaceuticals, Inc.
Malignant Melanoma
A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide
The purpose of the study is to determine Efficacy, Safety and Tolerability of MDX-010 (BMS-734016) administered with or without Prophylactic Oral Budesonide.
- Trial name
- NCT00135408
- Testing
- Ipilimumab+ Budesonide
- Where
- 10 sites in United States, Canada and 4 more
- Volunteers
- 115 people
- Sponsor
- Bristol-Myers Squibb
HER2-PositiveRecurrent or Metastatic Breast Cancer
A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer
To evaluate the efficacy and safety of SHR-A1811 with or without pertuzumab versus trastuzumab, pertuzumab and docetaxel in HER2-Positive Recurrent or Metastatic Breast Cancer
- Trial name
- NCT06057610
- Testing
- SHR-A1811 Injection, SHR-A1811 Injection ； Pertuzumab Injection, Trastuzumab Injection；Pertuzumab Injection ； Docetaxel Injection
- Where
- China
- Volunteers
- 868 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Triple Negative Breast Cancer
A Study of SYS6043 Versus Investigator's Choice Chemotherapy as First-Line Treatment in Patients With Unresectable Locally Recurrent or Metastatic Triple-Negative Breast Cancer
This is a randomized, controlled, open-label, multicenter study. Eligible participants are patients with unresectable locally recurrent or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic…
- Trial name
- NCT07879911
- Testing
- Enter a brief, descriptive name for the intervention. Use a non-proprietary (generic) name, if available. SYS6043, Investigator's Choice of Chemotherapy (paclitaxel，nab paclitaxel，capecitabine，eribulin，carboplatin）
- Volunteers
- 550 people
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Breast Neoplasms
A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
This is a randomized, multicenter, open-label, two-arm study in treatment-naive participants with operable, locally advanced, or inflammatory, centrally-assessed HER2-positive early breast cancer (EBC) whose primary tumors were…
- Trial name
- NCT02131064
- Testing
- Carboplatin, Docetaxel, Pertuzumab
- Where
- 79 sites in United States, Belgium and 8 more
- Volunteers
- 444 people
- Sponsor
- Hoffmann-La Roche
Melanoma
Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma
The purpose of this study is to determine whether a vaccine composed of patients' own melanoma cells treated with the chemical, dinitrophenyl (DNP)(called a hapten), is safe and stimulates an immune response to patients' own…
- Trial name
- NCT00257465
- Testing
- Autologous, DNP-modified vaccine (M-Vax), Autologous, DNP-Modified Melanoma Vaccine, Autologous, DNP-Modified Vaccine
- Where
- 7 sites in United States
- Volunteers
- 82 people
- Sponsor
- AVAX Technologies
Breast Cancer
A Multicenter, Double-blind, Randomized, Parallel-group, Phase III Study of the Efficacy and Safety of QL1701 Plus Docetaxel Versus Herceptin® Plus Docetaxel as First Line Therapy in Patients With HER2-positive Metastatic Breast Cancer
This is a Phase III, double-blind, randomized multicenter study to compare the efficacy and to evaluate the safety and immunogenicity of QL1701 and Herceptin® in patients with human epidermal growth factor receptor 2…
- Trial name
- NCT05629949
- Testing
- QL1701, Herceptin®, Docetaxel
- Where
- China
- Volunteers
- 474 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Melanoma (Skin)
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma
RATIONALE: Vaccines made from a person's white blood cells combined with melanoma antigens may make the body build an immune response to tumor cells.
- Trial name
- NCT00004025
- Testing
- aldesleukin, dendritic cell-gp100-MART-1 antigen vaccine
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Genzyme, a Sanofi Company
Triple Negative Breast Cancer (TNBC)
Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer
This study tests an investigational cancer vaccine called ITI-5000 in people who have completed standard treatment for early-stage triple-negative breast cancer (TNBC).
- Trial name
- VITAL-TNBC (NCT07652242)
- Testing
- ITI-5000 mRNA Vaccine, Pembrolizumab, Olaparib
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Immunomic Therapeutics, Inc.
Stage III Melanoma, Stage IV Melanoma
Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors
This is a study of transfusion of TBX-3400 in patients with stage III and IV melanoma resistant or refractory to Immune Checkpoint Inhibitors.
- Trial name
- NCT03385486
- Testing
- TBX-3400
- Where
- 2 sites in United States
- Volunteers
- 72 people
- Sponsor
- Taiga Biotechnologies, Inc.
Breast Cancer
A Phase III Clinical Study of HRS-6209 Plus Letrozole as First-line Therapy in Patients With Advanced or Metastatic Breast Cancer
The purpose of this study is to investigate the efficacy and safety of HRS-6209 in combination with letrozole compared with dalpciclib or palbociclib in combination with aromatase inhibitor in patients with advanced or metastatic…
- Trial name
- NCT07894328
- Testing
- HRS-6209 + Letrozole, Dalpciclib/Palbociclib + Letrozole/Anastrozole
- Where
- China
- Volunteers
- 1,050 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Melanoma
A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma
The objectives of this study are to compare the anti-tumor activity as measured by Progression Free Survival (PFS) and tolerability of Sorafenib in combination with Paclitaxel and Carboplatin versus Paclitaxel and Carboplatin in…
- Trial name
- NCT00111007
- Testing
- Sorafenib (Nexavar, BAY43-9006), Carboplatin/Paclitaxel
- Where
- 66 sites in United States, Australia and 5 more
- Volunteers
- 270 people
- Sponsor
- Bayer
Breast Neoplasms
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
This is a Phase III trial where participants will be randomized to two treatment groups, which means participants will be assigned by equal chance to a treatment group.
- Trial name
- NCT07173751
- Testing
- Pumitamig, Nab-paclitaxel/Paclitaxel, Gemcitabine
- Where
- 224 sites in United States, Argentina and 17 more
- Volunteers
- 558 people
- Sponsor
- BioNTech SE
Melanoma
A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called cemiplimab (each individually called a "study drug" or called "study drugs" when…
- Trial name
- NCT05608291
- Testing
- Fianlimab, Cemiplimab, Pembrolizumab
- Where
- 211 sites in United States, Argentina and 20 more
- Volunteers
- 1,564 people
- Sponsor
- Regeneron Pharmaceuticals
Melanoma
Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma
The purpose of this study is to determine if BMS-663513 administered in combination with ipilimumab to patients with advanced malignant melanoma is safe and tolerable
- Trial name
- NCT00803374
- Testing
- AntiCD137, Ipilimumab
- Where
- 7 sites in United States
- Sponsor
- Bristol-Myers Squibb
Breast Cancer
Evaluate the Efficacy and Safety of Genexol®-PM Compared to Genexol® in Recurrent or Metastatic Breast Cancer
Phase III trial to evaluate the efficacy and safety of Genexol®-PM compared to Genexol® in subjects with recurrent or metastatic breast cancer.
- Trial name
- NCT00876486
- Testing
- Genexol-PM®, Genexol®
- Where
- South Korea
- Volunteers
- 213 people
- Sponsor
- Samyang Biopharmaceuticals Corporation